Clinical correlation of hormone receptor status in epithelial ovarian cancer

Masood, Shahla; Heitmann, Jeffrey; Nuss, Robert C.; Benrubi, Guy I.

doi:10.1016/0090-8258(89)90107-8

Cited by 28 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In endometrial and breast carcinomas, steroid hormone receptor status correlates well with response to hormonal manipulation and prognosis (McGuire, 1978;Benraad et al, 1980;Ehrlich et al, 1981;Kaupilla, 1984). However, in epithelial ovarian carcinoma, the prognostic significance of tumour ER status among patients still remains controversial (Bizzi et al, 1988;Masood et al, 1989;Sevelda et al, 1990;Rao and Slotman, 1991;Hempling et al, 1998).…”

mentioning

confidence: 99%

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription -polymerase chain reaction (RT -PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERa. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERa were evaluated by RT -PCR in 22 cases. The expression for EBAG9 and ERa was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P ¼ 0.0402) and advanced disease (P ¼ 0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P ¼ 0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (Po0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERa mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERa expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.

show abstract

mentioning

confidence: 99%

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…There is some evidence that ER expression does not play a prognostic role in ovarian cancer (Masood et al 1989, Harding et al 1990, Rose et al 1990, Sevelda et al 1990, Slotman et al 1990, Scambia et al 1995. In our latest experience of 177 primary ovarian cancer patients, no significant association between ER and overall and progression-free survival was observed at any of the cutoff levels tested.…”

Section: Er and Pr Expression And Survivalmentioning

confidence: 84%

“…Other authors (Sutton et al 1986, Kuhnel et al 1987, Anderl et al 1988, Bizzi et al 1988, Masood et al 1989, Harding et al 1990, Sevelda et al 1990, Slotman et al 1990, Scambia et al 1995 did not find any correlation between steroid hormone positivity and histotype. The relationship between steroid receptors and grade of differentiation is not clear; some authors found that well-differentiated tumours more frequently contain ER (Ford et al 1983, Iversen et al 1986 or both ER and PR (Creasman et al 1981), but many other studies (Gronroos et al 1984, Sutton et al 1986, Toppila et al 1986, Kuhnel et al 1987, Bizzi et al 1988, Masood et al 1989, Harding et al 1990, Rose et al 1990, Sevelda et al 1990, Slotman et al 1990, Scambia et al 1995 did not confirm these results.…”

Section: Steroid Hormone Receptors and Ovarian Cancermentioning

confidence: 93%

“…Spona et al (1983) demonstrated a higher incidence (63%) of ER+/PR+ in patients older than 60 years of age than in younger subjects (36%) whereas other authors (Sevelda et al 1990, Scambia et al 1995 reported that PR positivity is more frequently associated with older age. In most studies, no definitive associations between ER, PR expression and stage of disease have been demonstrated , Gronroos et al 1984, Iversen et al 1986, Anderl et al 1988, Bizzi et al 1988, Masood et al 1989, Rose et al 1990, Slotman et al 1990. As far as the relationship between steroid receptors and histology is concerned, some authors reported that endometrioid and serous tumours more frequently contain PR or ER (Quinn et al 1982, Ford et al 1983, Sutton et al 1986, Toppila et al 1986, Rose et al 1990) while (Toppila et al 1983, Gronroos et al 1984, Scambia et al 1995.…”

Section: Steroid Hormone Receptors and Ovarian Cancermentioning

confidence: 99%

“…Some studies also analysed the effects of chemotherapy exposure in primary ovarian tumours: Sutton et al (1986) reported that ER levels were lower in ovarian carcinomas after chemotherapy while Richman et al (1985) reported that there was little if any difference in ER levels before and after chemotherapy as also shown by Holt et al (1986), Masood et al (1989) and Rose et al (1990). Lower PR levels have been reported in chemotherapy-exposed ovarian tumours (Sutton et al 1986).…”

Section: Steroid Hormone Receptors and Ovarian Cancermentioning

confidence: 99%

See 2 more Smart Citations

Oestrogen and progesterone receptors in ovarian carcinoma

Scambia

D'Agostino

Fagotti

et al. 1998

Endocrine Related Cancer

View full text Add to dashboard Cite

Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary

Geisler

Wiemann

Miller

et al. 1995

Journal of Surgical Oncology

View full text Add to dashboard Cite

Malignant mixed mesodermal tumors of the ovary occur in less than 1% of cases of ovarian cancer. They have a dismal prognosis and the most effective type of therapy is still not known. All cases of malignant mixed mesodermal tumor of the ovary between January 1, 1985 and May 1, 1994 operated on by the gynecologic oncology service are the subject of this report. Data were obtained from the hospital and office records of the patients. Nine patients who had their primary surgery by the gynecologic oncology service were found to have the diagnosis of malignant mixed mesodermal tumor of the ovary. Homologous tumors were found in five patients and heterologous tumors in four. Homologous tumors (mean survival 15.2 months) showed a better survival than heterologous tumors (mean survival 6.5 months; P = 0.001). An elevated estrogen receptor status was shown to correspond to longer survival (P < 0.0001). Six specimens were considered to be estrogen receptor positive and three were receptor negative. The mean survival in those patients who had a positive estrogen receptor status, 13.7 months, with a median of 7.5 months was significantly higher than those who were not positive, 6.7 months (P = 0.019) with a median of 6.25 months. All specimens were progesterone receptor negative. Malignant mixed mesodermal tumors of the ovary have a dismal prognosis, no effective therapy, and controversial prognostic indicators. Increasing estrogen receptor status appeared to correlate with longer mean survival. Larger, multi-institutional studies need to be done to determine the overall significance of these findings.

show abstract

Clinical correlation of hormone receptor status in epithelial ovarian cancer

Cited by 28 publications

References 16 publications

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Oestrogen and progesterone receptors in ovarian carcinoma

Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary

Contact Info

Product

Resources

About